X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
ZONISADE is first and only zonisamide formulation for oral liquid administration to be approved by FDA, as an adjunctive therapy for the treatment of partial seizures in adults and pediatric patients aged 16 years and older with epilepsy.
Lead Product(s): Zonisamide
Therapeutic Area: Neurology Product Name: Zonisade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
Zonisade is the first and only zonisamide formulation for oral liquid administration to be approved by the US Food and Drug Administration as an adjunctive therapy for the treatment of partial seizures in adults and paediatric patients aged 16 years and older with epilepsy.
Lead Product(s): Zonisamide
Therapeutic Area: Neurology Product Name: Zonisade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Azurity Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
The application was submitted for the treatment of partial seizures in patients with epilepsy. Zonisamide is one of Eton’s three neurology-focused oral liquid product candidates that have been submitted to the FDA.
Lead Product(s): Zonisamide
Therapeutic Area: Neurology Product Name: ET-104
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
ET-104 is one of Eton’s three neurology-focused liquid product candidates, along with ET-105 (lamotrigine oral suspension) and ET-101 (topiramate oral solution).
Lead Product(s): Zonisamide
Therapeutic Area: Neurology Product Name: ET-104
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
